Valuation: Verastem, Inc.

Market Cap 500M 434M 405M 372M 703M 47.56B 711M 4.77B 1.87B 23.78B 1.88B 1.84B 78.78B P/E 2026 *
-3.59x
P/E 2027 * -5.07x
Enterprise Value 335M 291M 271M 249M 471M 31.87B 476M 3.2B 1.25B 15.93B 1.26B 1.23B 52.78B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 1.63x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+2.20%
1 week-6.50%
Current month+0.43%
1 month+30.61%
3 months-2.10%
6 months-14.21%
Current year-24.55%
1 week 5.54
Extreme 5.54
6.31
1 month 4.3
Extreme 4.3
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%-6.50%-3.08%-47.80% 500M
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
-0.57%-0.78%-16.64%-13.86% 23.33B
+0.53%-5.03%-11.10%+349.70% 21.34B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.99%-0.55%+52.68%+177.26% 13.84B
+3.72%+4.09%+442.30%+182.12% 12.12B
+5.82%-5.01%+63.98%+163.17% 11.14B
Average +3.05%-1.20%+83.81%+127.54% 22.31B
Weighted average by Cap. +3.76%+0.43%+62.33%+117.50%

Financials

2026 *2027 *
Net sales 102M 88.45M 82.47M 75.76M 143M 9.69B 145M 972M 380M 4.84B 383M 374M 16.05B 178M 155M 144M 133M 251M 16.96B 254M 1.7B 665M 8.48B 670M 655M 28.1B
Net income -166M -144M -134M -123M -233M -15.75B -235M -1.58B -618M -7.87B -622M -608M -26.08B -142M -123M -115M -106M -200M -13.51B -202M -1.36B -530M -6.76B -533M -522M -22.38B
Net Debt -165M -143M -134M -123M -232M -15.7B -235M -1.57B -616M -7.85B -620M -606M -26B -210M -182M -170M -156M -295M -19.94B -298M -2B -782M -9.97B -787M -770M -33.02B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
05/08/26 USD 5.825 +2.37% 894,445
03/08/26 USD 5.690 -1.90% 1,288,075
31/07/26 USD 5.800 -4.92% 1,857,262
30/07/26 USD 6.100 +1.50% 1,451,955
29/07/26 USD 6.010 -3.53% 2,249,888
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.690USD
Average target price
15.00USD
Spread / Average Target
+163.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock